Welcome, fellow medical investor. I'm not quite sure what your points are other than that it is indeed difficult to develop a HSV-1 vaccine. The preclinical studies on mice were and are absolutely necessary before progressing Phase 1 trials on humans. As for the 'very small' sample sizes, 20-25 subjects is standard for Phase 1 and definitely statistically significant. So I really don't know why you brought up either points. But I do agree that if there is a robust immune response in Phase II trials, Professor Frazer has won the global research race to cure HSV-1. I reckon he's got this. :)
updated ballieu report - target range 25-55c, page-43
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |